Some of the nation's largest hospital and provider groups are speaking out against the Trump administration's decision to freeze risk adjustment payments.

If you’re an off-patent drug sitting pretty with no rivals—generic or otherwise—enjoy it while you can. To stir up competition, FDA is looking at importing drugs that are approved in other countries but not yet in the U.S.

U.S. regulators proposed new guidelines Tuesday to make it easier for some common medicines to be sold without a prescription — and more convenient for consumers to get them.

The Trump administration has been pushing for the return of short-term health plans and association health plans, two types of coverage that are exempt from Affordable Care Act requirements and could offer an affordable alternative to consumers who feel priced out of the Obamacare marketplace. But some California advocates say these plans offer shoddy coverage and pose a threat to the stability of the healthcare system.

House Ways and Means Committee Chairman Kevin Brady (R-Texas) said Monday that he is in talks with the Trump administration about ways to restart key ObamaCare payments that the administration abruptly suspended this month.

In a little more than 24 hours, through public shaming and a phone call with Pfizer CEO Ian Read, President Donald Trump convinced the U.S. drug giant to reverse dozens of July price increases—at least temporarily. The extraordinary move signals that pharma players are willing to cede to the president, even as Pfizer and Read have previously resisted limits on their pricing power.